BRIEF—Faron Pharmaceuticals inks deal with CRO ahead of pivotal readout

London-listed Faron Pharmaceuticals has agreed terms for German CRO Lyocontract to manufacture Traumakine, for the treatment of acute respiratory distress syndrome (ARDS).

The firm will complement the primary site currently operated by Rentschler Biopharma under a separate deal.

Faron is making commercial preparations in the event of positive results from the pivotal pan-European INTEREST trial, data from which is expected in the coming months.

Chief executive Markku Jalkanen said the deal would enable Faron “to provide Traumakine supply for early access programs as well as for later market demand in the event of product approval,” adding that “recent positive FDA advice” would “expedite Traumakine’s potential route to US markets.”